ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain cancers and other cancers.  ImmunoCellular has concluded a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell (DC)-based immunotherapy targeting multiple stem cell-associated antigens for newly diagnosed glioblastoma.  ImmunoCellular’s pipeline also includes: ICT-121, a DC immunotherapy targeting the CD133 stem cell-antigen in recurrent glioblastoma; ICT-140, a DC immunotherapy targeting stem cell-associated antigens for ovarian cancer; and the Stem-to-T cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Copyright 2015 by Immunocellular Therapeutics, Ltd.
All Rights Reserved